In last trading session, Ginkgo Bioworks Holdings Inc (NYSE:DNA) saw 0.55 million shares changing hands with its beta currently measuring 1.14. Company’s recent per share price level of $8.72 trading at $0.46 or 5.57% at ring of the bell on the day assigns it a market valuation of $501.22M. That closing price of DNA’s stock is at a discount of -762.39% from its 52-week high price of $75.20 and is indicating a premium of 39.68% from its 52-week low price of $5.26. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 1.43 million shares which gives us an average trading volume of 1.30 million if we extend that period to 3-months.

For Ginkgo Bioworks Holdings Inc (DNA), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 3.83. Splitting up the data highlights that, out of 5 analysts covering the stock, 2 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 1 suggested the stock as a Hold whereas 2 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of 0 in the current quarter.

Ginkgo Bioworks Holdings Inc (NYSE:DNA) trade information

Upright in the green during last session for gaining 5.57%, in the last five days DNA remained trading in the green while hitting it’s week-highest on Friday, 11/29/24 when the stock touched $8.72 price level, adding 0.23% to its value on the day. Ginkgo Bioworks Holdings Inc’s shares saw a change of -87.10% in year-to-date performance and have moved 32.32% in past 5-day. Ginkgo Bioworks Holdings Inc (NYSE:DNA) showed a performance of 11.22% in past 30-days. Number of shares sold short was 7.32 million shares which calculate 6.57 days to cover the short interests.

Wall Street analysts have assigned a consensus price target of 6.5 to the stock, which implies a fall of -34.15% to its current value. Analysts have been projecting 4.35 as a low price target for the stock while placing it at a high target of 12. It follows that stock’s current price would jump 50.11% in reaching the projected high whereas dropping to the targeted low would mean a gain of 50.11% for stock’s current value.

Ginkgo Bioworks Holdings Inc (DNA) estimates and forecasts

Statistics highlight that Ginkgo Bioworks Holdings Inc is scoring comparatively higher than the scores of other players of the relevant industry. The company lost -58.75% of value to its shares in past 6 months, showing an annual growth rate of 35.77% while that of industry is 17.70. Apart from that, the company came raising its revenue forecast for fiscal year 2024. This year revenue growth is estimated to fall -9.45% from the last financial year’s standing.

5 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 44.43M for the same. And 3 analysts are in estimates of company making revenue of 43.81M in the next quarter. Company posted 34.76M and 37.94M of sales in current and next quarters respectively a year earlier.

In 2024, company’s earnings growth rate is likely to be around 45.22% while estimates for its earnings growth in next 5 years are of 31.20%.

Ginkgo Bioworks Holdings Inc (NYSE:DNA)’s Major holders

Insiders are in possession of 6.16% of company’s total shares while institution are holding 68.56 percent of that, with stock having share float percentage of 73.06%. Investors also watch the number of corporate investors in a company very closely, which is 68.56% institutions for Ginkgo Bioworks Holdings Inc that are currently holding shares of the company. VIKING GLOBAL INVESTORS LP is the top institutional holder at DNA for having 143.09 million shares of worth $47.83 million. And as of 2024-06-30, it was holding 7.1383 of the company’s outstanding shares.

The second largest institutional holder is VANGUARD GROUP INC, which was holding about 138.96 million shares on 2024-06-30. The number of shares represents firm’s hold over 6.9327 of outstanding shares, having a total worth of $46.46 million.

On the other hand, Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund are the top two Mutual Funds which own company’s shares. As of Jun 30, 2024 , the former fund manager was holding 1.12 shares of worth $9.75 million or 2.48% of the total outstanding shares. The later fund manager was in possession of 521.82 shares on Jun 30, 2024 , making its stake of worth around $4.54 million in the company or a holder of 1.15% of company’s stock.